MyFinsight
Home
Blog
About
Contact
Download
Download image
Non Us
$3,571,500K
(-10.18%↓ Y/Y)
US
$3,547,900K
(9.59%↑ Y/Y)
Royalty Attributed To
OCREVUS
$1,414,900K
Biogen's share of pre-tax
profits in the u.s. for...
$420,200K
Royalty revenue on sales
of ocrevus-Roche...
$25,500K
US
$414,700K
(4.99%↑ Y/Y)
Asia
$307,400K
(19.52%↑ Y/Y)
Europe Excluding
Germany
$10,800K
(2600.00%↑ Y/Y)
Product
$7,119,400K
(-1.30%↓ Y/Y)
Revenues From Anti
CD20Therapeutic Programs
$1,860,600K
(6.33%↑ Y/Y)
Contract Manufacturing
Royalty And Other...
$732,900K
(12.30%↑ Y/Y)
Alzheimers Collaboration
$177,700K
(196.66%↑ Y/Y)
Revenues
$9,890,600K
(2.22%↑ Y/Y)
Income before income
tax (benefit)...
$1,556,500K
Total cost and expense
$8,334,100K
(7.26%↑ Y/Y)
Net income
$1,292,900K
(-20.79%↓ Y/Y)
Income tax (benefit)
expense
$263,600K
(-3.73%↓ Y/Y)
Selling, general and
administrative
$2,433,600K
(1.24%↑ Y/Y)
Cost of sales,
excluding amortization...
$2,404,200K
(4.06%↑ Y/Y)
Research and development
$1,778,600K
(-12.89%↓ Y/Y)
Amortization and impairment
of acquired...
$515,000K
(15.29%↑ Y/Y)
Acquired in-process
research and...
$471,800K
Other (income)
expense, net
-$305,600K
(11.06%↑ Y/Y)
Collaboration profit
sharing/(loss reimbursement)
$290,200K
(14.07%↑ Y/Y)
Impairment of rou asset
$52,900K
Restructuring charges
$48,600K
(60.93%↑ Y/Y)
(gain) loss on fair
value remeasurement...
-$33,600K
(-21.30%↓ Y/Y)
Net income
attributable to biogen inc
$1,292,900K
(-20.79%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)